About PharmaJet

PharmaJet is a commercial stage MedTech Company with US and International distribution.

We work side by side with our partners to enable greater access to life improving pharmaceuticals

PharmaJet’s Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use.

The PharmaJet Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. An FDA Master File was established in August of 2017 as a precursor to 510(k) and Tropis received WHO Pre-Qualification (PQS) in June of 2018.

The innovative PharmaJet Stratis® Needle-Free Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis Needle-free Injector was approved for delivery of an influenza vaccine to deliver needle-free flu shots.

The PharmaJet Team

Chris Cappello

President and Chief Executive Officer

Mr. Cappello was appointed Chief Operating Officer in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Chris has over 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, clearance and launch of both reusable and high volume disposable medical devices. Prior to joining PharmaJet, he drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. Chris has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and his Project Management Professional certification.

Jeffrey A. Jordan

Chief Financial Officer

Mr. Jordan has more than 25 years of experience in corporate finance. In his previous role, he directed the global finance functions for the Laboratory Products Group of Thermo Fisher Scientific, supporting $1.9B in annual revenue and 10,000 employees. Jeff has worked in several industries including life science tools, telecommunications and industrial chemicals. He has extensive experience in strategic planning, forecasting, significant capital investments, acquisitions and integration activities. Jeff has a Bachelor of Science degree in Mechanical Engineering from the United States Military Academy at West Point and an MBA from the University of Maryland.

Dan Mallon

Senior Vice President, Corporate Development

Mr. Mallon has 25 years of corporate development experience in the biopharmaceutical and medical device industries, where he has successfully identified market opportunities and stimulated product/business growth. He brings specific expertise in corporate strategy and development, alliance management, product marketing and government contracting. Prior to joining PharmaJet, Dan served in business development leadership positions at Ellume USA, RRD International and Emergent BioSolutions. He holds a Bachelor of Arts degree in Zoology from Miami University, and an MBA in Finance from the University of Maryland.

Paul LaBarre

Vice President, Global Business Development

Mr. LaBarre has 25 years of Medical Technology experience across the innovation value chain including regulatory, strategy, research, product development, and market analysis. He has held key business development roles at prominent healthcare organizations including UNICEF and PATH, as well as other health innovation organizations. Most recently he was Senior Vice President, Access and Innovation for SightLife, the world’s leading eye bank. Paul holds a Bachelor of Science degree in Mechanical Engineering from Northwestern University, a Master of Medical Engineering from the University of Washington, and an MBA from Mount Vernon Nazarene University.

Nathalie Landry

Chief Scientific Officer

Ms. Landry has over 30 years of experience in the successful development of a new technology platform as well as innovative vaccines and pharmaceuticals from proof-of-concept to late-stage clinical trials and regulatory approval. Prior to joining PharmaJet, she was Executive Vice President, Scientific and Medical Affairs at Medicago, an international leader in plant-based technology producing vaccines and therapeutics, where she led all R&D activities, analytical and process development, preclinical and clinical development, medical affairs, and pharmacovigilance activities. She has published over 25 articles in major international scientific journals, two book chapters and is co-inventor on 8 patent families. Nathalie holds a Master of Microbiology-Immunology and an MBA from the Université Laval.

Troy Chapman

Vice President, Operations

Mr. Chapman has more than 30 years of experience in the medical device industry across the fields of electrophysiology, electrosurgery, embolic coils and radioactive pharmaceuticals. Prior to joining PharmaJet he held engineering and leadership positions at Cardinal Health, ConMed and Covidien where he was responsible for research, development, and manufacturing. Troy has a Bachelor of Science degree in Mechanical Engineering from Purdue University.

Marie Mazur, PharmD

Chairman

Ms. Mazur has served on the Board of Directors since 2020 and was appointed Chairman in 2023. She is a global business executive with 30+ years of pharmaceutical and vaccine industry experience including Sanofi, 3M, GSK and CSL Seqirus. She also serves on the Strategic Advisory Group of the Partnership for Influenza Vaccine Introduction (PIVI), a program from the Task Force for Global Health in partnership with the US Centers for Disease Control and Prevention. Marie holds a doctorate in Pharmacy and master’s degree in Regulatory Affairs from Paris (France) University, and an International Executive Degree in Business Administration (IEP) from INSEAD Business School.

Chris Cappello

President and Chief Executive Officer

Mr. Cappello was appointed Chief Operating Officer in 2018, and President and Chief Executive Officer in 2020. In this position, he is responsible for running all facets of the business. Mr. Cappello has over 15 years of direct management experience in medical device development and sales, and has spent his career managing the successful design, development, clearance and launch of both reusable and high volume disposable medical devices. Previously Chris drove the development of disruptive medical device technologies at companies such as AlloSource and Applied Medical. He has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and his Project Management Professional certification.

Heather Callender-Potters

Chief Advocate & Shareholder Relations Officer

One of the co-founders and active in the management of PharmaJet, Heather has 23 years of private equity fund management and international investment experience across multiple jurisdictions, managing individual investments and financial investment consortiums.  She has a BA in International Management from Claremont McKenna College and an MBA from Wharton, the University of Pennsylvania.

Tony Allard

Mr. Allard is President of Hearthstone Investments.  He holds a BA and LLB from the University of Alberta.

Spike Buckley

Mr. Buckley has a background as a commercial real estate developer, with investments spanning the US and Canada. He is an active angel investor in high- tech and bio-tech companies, which includes medical devices and tools that aid in drug delivery and diagnostic activities. Spike is an active board participant in the Colorado Veterinary Medical Foundation, Alameda Corridor Business Improvement District and CryptoMill Technologies. He holds a BA in Economics from the University of Colorado.

Gordon Clancy

Mr. Clancy is a private investor, and a former Managing Partner of Citigroup Venture Capital International, a global private equity fund that invested primarily in emerging markets in a wide variety of industries including pharmaceuticals and medical equipment. Prior to his involvement in private equity, he worked in various roles in the Citigroup capital markets and trading businesses. He holds a Bachelor of Arts degree in Commerce and Economics from University of Toronto and an MBA from the Rotman School of Management, University of Toronto.

Nanette Cocero, Ph.D.

Dr. Cocero is a recognized leader in the global pharmaceutical industry with 25+ years of experience most recently as the Global President of Pfizer Vaccines. In this role, she led a diverse, >$30B portfolio and drove the development, marketing and delivery of innovative vaccines including the Pfizer-BioNTech COVID-19 vaccine. She holds a Bachelor of Science degree in Chemistry from Cornell University, an MBA from The Wharton Business School and a doctorate in Pharmacology from the University of Pennsylvania.

Kim Duncan

Mr. Duncan is currently the CEO of ConserV Bioscience, a UK-based late-stage vaccine development company. He began his career at Goldman Sachs in 1987 and went on to have a 20-year career in the investment business where he led teams taking principal risk. He has been an active angel investor since 2006, focusing on equity investments in promising, early-stage biotechnology companies and currently serves on the boards of six companies. He earned a Bachelor of Science degree in Electrical Engineering from Yale University, an MS in Biotechnology and an MS in Physiology and Pharmacology both from Georgetown University.

John Hynes

Mr. Hynes is the Chief Financial Officer and a Board member for QC Ware Corp, a software company focused on high-powered algorithms for drug discovery and finance. Previously, he spent 30 years as a professional investor with Fidelity Investments, Emso Asset Management and Watermark Management. He has extensive experience with health care, biotech, and technology companies, both public and private. He has a BA in Economics from Dartmouth College and an MBA from The Wharton School at the University of Pennsylvania.

Markus Pedriks

Mr. Pedriks is an investor, as well as a professional private equity fund manager. He is skilled in operational leadership and entrepreneurial activities, in Europe and North America, in health, media, telecommunications, entertainment and real estate.  He holds a BA in Economics from McGill University and an MBA from IMD, Lausanne.

Marian Wentworth

Ms. Wentworth, a seasoned global health executive, is President and CEO of Management Sciences for Health, a nonprofit organization that works with low- and middle-income markets across 30 countries to strengthen their health systems. Previously she held executive roles at Merck & Co., most recently as Vice President, Global Vaccines Strategy and Innovation, where she was responsible for strategy for the $6 billion global vaccines business. She is also Chair of the Board of Medsource, a privately held group purchasing organization in Kenya. Marian holds a Bachelor of Arts degree in Mathematics from Harvard University.

Meet the subject matter experts that will assist the company to demonstrate how our delivery technology improves the performance of vaccines and therapeutics.

Infectious Diseases SAB
Cornelia Dekker, M.D.

Professor of Pediatrics (Infectious Diseases), Emerita, Stanford University School of Medicine

  • Former Vice President, Clinical Research and Medical Affairs, Chiron Vaccines
  • Former Medical Director, Stanford-LPCH Vaccine Program
James Merson, Ph.D.

Chief Virology Officer, Stealth Oncology Company

  • Former SVP and CSO, Vaccine Immunotherapeutics Research Unit, Pfizer
  • Former Global Therapeutic Area Head, Infectious Diseases, Janssen
Bali Pulendran, Ph.D.

Co-Director, Institute for Immunity, Transplantation and Infection, Stanford University, and Violetta L. Horton Professor of Pathology, and of Microbiology and Immunology

  • World renowned immunologist, and a pioneer of System Biology Approaches to predict the efficacy of vaccines, and decipher new correlates of protection against infectious diseases
  • Author/co-author of 260+ publications
Brian Ward, MDCM

Professor of Infectious Diseases/Microbiology, McGill University

  • Former Medical Officer, Medicago Inc.
  • Director of the McGill Vaccine Study Center
  • 30+ years of translational research at McGill University
Oncology SAB
Michael Gibson, M.D., Ph.D., FACP

Director, Translational Research for Esophago-Gastric Cancer (EGC) at the Vanderbilt-Ingram Cancer Center (VICC)

  • Associate Professor of Medicine at the Vanderbilt University Medical Center
  • Osler Medical Residency and Medical Oncology Fellowship, Johns Hopkins Hospital and PhD, Clinical Investigation (Johns Hopkins University Bloomberg School of Public Health)
Stephanie Mazzei, MSc

Founder and Director, OncoLogic Inc.

  • Global Oncology Strategy Advisor
  • Serial Entrepreneur and Board Leader
  • Former Change Agenda Leader, Global Oncology Business Unit, Eli Lilly and Company
Douglas McNeel, M.D., Ph.D.

Professor of Medicine, Director, Solid Tumor Immunology Research, Co-Director, University of Wisconsin Prostate SPORE, UW Carbone Cancer Center

  • Genitourinary medical oncologist with expertise in prostate cancer
  • Laboratory and clinical translational research focus on anti-tumor vaccines
  • Specific laboratory focus on DNA vaccines and mechanisms of tumor immune resistance
James Merson, Ph.D.

Chief Virology Officer, Stealth Oncology Company

  • Former SVP and CSO, Vaccine Immunotherapeutics Research Unit, Pfizer
  • Former Global Therapeutic Area Head, Infectious Diseases, Janssen
Patrick Ott, M.D., Ph.D.

Clinical Director, Melanoma Center, Dana Farber Cancer Institute

  • Associate Professor of Medicine, Harvard Medical School
  • Clinical and Translational Investigator, Immunotherapy Trials, Personalized Cancer Vaccines
Menu